Изучение роли неканонической молекулы главного комплекса гистосовместимости человека HLA-E в регуляции противоопухолевого иммунного ответа
Диссертация
Описано несколько механизмов, благодаря которым опухоли могут избегать иммунологического надзора: возникновение вариантов раковых клеток с утерей антигенов, локальная экспрессия ингибиторных молекул, таких как трансформирующий фактор роста (TGF-P) и Fas лиганд, снижение уровня процессинга и презентации антигенов, а также потеря молекул МНС на клеточной поверхности. Казалось бы, в случае снижения… Читать ещё >
Список литературы
- Бачдуева И.А. Противоопухолевые вакцины // Практ. Онкол. 2003. — Т. 4, № 3. -С. 157−166.
- Михайлова КН., Лукашина М. И., Барышников А. Ю. и др. Меланомные клеточные линии как основа противоопухолевых вакцин // Вестн. Росс. Акад. Мед. Наук. -2005.-Т. 7.-С. 37−40.
- Моисеенко В.М. Возможности вакцинации меланомы кожи // Практ. Онкол. 2001. -Т. 8, № 4.-С. 58−64.
- Моисеенко В.М. Моноклональные антитела в лечении злокачественных опухолей // Практ.Онкол. 2003. — Т. 4, № 3.- С. 148−156.
- Adam J.K., Odhav В., Bhoola K.D. Immune responses in cancer // Pharm. Therapeut. -2003.-Vol. 99.-P. 113−132.
- Adams G.P., Weiner L.M. Monoclonal antibody therapy of cancer // Nat. Biotechnol. -2005.-Vol. 23, № 9.-P. 1147−1157.
- Ansari M.J.I., SalamaA.D., Chitnis T. et al. The programmed death-1 (PD-1) pathway regulates autoimmune diabetes in nonobese4 diabetic (NOD) mice // J. Exp. Med. -2003.-Vol. 198.-P. 63−69.
- Atzpodien J., Hoffmann R., Franzke M. et al. Thirteen-year, long-term efficacy of interferon 2 alpha and interleukin 2-based home therapy in patients with advanced renal cell carcinoma // Cancer. 2002. — Vol. 95. — P. 1045−1050.
- Banchereau J., Palucka A.K., Dhodapkar M. et al. Immune and clinical responses in patients with metastatic melanoma to CD34+ progenitor-derived dendritic cell vaccine //Cancer Res.-2001.-Vol. 61.-P. 6451 6458.
- Barrett D.M., Gustafson K.S., Wang J. et al. A GATA factor mediates cell type-restricted induction of HLA-E gene transcription by gamma interferon // Mol. Cel. Biol. 2004. — Vol. 24, № 14. — P. 6194−6204.
- Banco Z, Bene L., Damjanovich L., Damjanovich S. INF-gamma rearranges membrane topography of MHC-I and ICAM-1 in colon carcinoma cells // Biochem. Biophys. Res. Commun. 2002. — Vol. 290. — P. 635−640.
- Belli F., Testori A., Rivoltini L. et al. Vaccination of metastatic melanoma patients with autologous tumor derived heat shock protein gp96-peptide complexes: clinical and immunologic findings // J. Clin. Oncol. 2002. — Vol. 20. — P. 4169 4180.
- Blattman J.N., Greenberg P.D. PD-1 blockade: rescue from a near-death experience // Nat. Immunol. 2006. — Vol. 7. — P. 227−228.
- Braud V., Jones E.Y., McMichael A. The human major histocompatibility complex class lb molecule HLA-E binds signal sequencederived peptides with primary anchor residues at positions 2 and 9 // Eur. J. Immunol. 1997. — Vol. 27. — P. 1164 1169.
- Braud V.M., Allan D.S., O’Callaghan C.A. et al. HLA-E binds to natural killer cell receptors CD94/NKG2A, В and С // Nature. 1998. — Vol. 391. — P. 795−799.
- Burowski R., Ernstoff M.S. Gore M.E. et al. Regulated interferon alfa-2b treatment for patients with solid tumours: a phasel/II study // J. Clin. Oncol. 2002. — Vol. 20. — P. 3841−3849.
- Cebon J., Jager E., Shackleton M.J. et al. Two phase I studies of low dose recombinant human IL-12 with Melan-A and influenza peptides in subjects with advanced malignant melanoma // Cancer Immun. 2003. — Vol. 3. — P. 3.
- Cerboni C., Mousavi-Jazi M., Wakiguchi H. et al. Synergistic effect of IFN-gamma and human cytomegalovirus protein UL40 in the HLA-E-dependent protection from NK cell-mediated cytotoxicity // Eur. J. Immunol. 2001. — Vol. 31. — P. 2926−2935.
- Cerudolo V., Kelly A., Elliott Т., Trowsdale J., Townsend A. Genes encoded in the major histocompatibility complex affecting the generation of peptides for TAP transport // Eur. J. Immunol. 1995. — Vol. 25. — P. 554−562.
- Chen E., Karr R.W., GinderGD. Negative and positive regulation of human leukocyte antigen class I gene transcription in K562 leukemia cells // Mol. Cell Biol. 1987. -Vol. 7, № 12.-P. 4572−4575.
- Chen L. Co-inhibitory molecules of the B7-CD28 family in the control of T-cell immunity // Nat. Rev. Immunol. 2004. — Vol. 4. — P. 336−346.
- Choi I.H., Zhu G., Sica G.L. et al. Genomic organization and expression analysis of B7-H4: an immune inhibitory molecule of the B7 family // J. Immunol. -2003. Vol. 171. — P. 4650−4654.
- Coley W.B. Treatment of inoperable malignant tumors with the toxins of erysipelas and the Bacillus prodigiosus // Trans. Amer. Surg. Assn. 1894. — Vol. 12. — P. 183−212.
- Collins A.V., Brodie D.W., Gilbert R.J.C. et al. The interaction properties of costimulatory molecules revisited// Immunity. -2002. Vol. 17. — P. 201−210.
- Cruz M" Eienich L.A., Smolarek T.A. et al. DNA sequence, chromosomal localization and tissue expression of the mouse proteasome subunits LMP10 (Psm 10) gene // Genomics. 1997. — Vol. 45. — P. 618−622.
- Curiel T.J., Wei S., Dong H. et al. Blockade of B7-H1 improves myeloid dendritic cell-mediated antitumor immunity // Nat. Med. 2003. — Vol. 9. — P. 562−567.
- Daeron M, Latour S., Malbec O. et al. The same tyrosine-based inhibition motif, in the intracytoplasmic domain of Fc gamma RIIB, regulates negatively BCR-, TCR-, and FcR-dependent cell activation // Immunity. 1995. — Vol. 5. — P. 635−646.
- DeLeo A.B., Jay G., Appella E. et al. Detection of a transformation-related antigen in chemically induced sarcomas and other transfromed cells of the mouse // Proc. Natl. Acad. Sci. USA. 1979. — Vol. 5. — P. 2420−2424.
- Derre L" Corvaisier M., Charreau B. et al. Expression and release of HLA-E by melanoma cells and melanocytes: potential impact on the response of cytotoxic effector cells // J. Immunol. 2006. — Vol. 177, № 5. — P. 3100−3107.
- Dohring C., Scheidegger D., Samaridis J. et al. A human killer inhibitory receptor specific for HLA-A // J. immunol. 1996. — Vol. 156. — P. 3098−3101.
- Dong H" Strome S.E., Salomao D.R. et al. Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion // Nat. Med. 2002. — Vol. 8. — P. 793−800.
- Dong H., Zhu G., Tamada K., Chen L. B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion // Nat. Med. 1999. — Vol. 5. -P. 1365−1369.
- Dorval Т., Palangie Т., Jouve M. et al. Treatment of metastatic melanoma with recombinant interferon alfa-2b // Invest. New Drugs. 1087. — Vol. 5. — P. S61-S63.
- Driscoll J., Brown M.G., Finley D., Monaco J.J. МНС-linked LMP gene products specially after peptidase activities of the proteasome // Nature. 1993. — Vol. 365. — P. 262−264.
- Dudley M.E., Wunderlich J.R., Robbins P.F. et al. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes // Science. 2002. -Vol. 298.- P. 850−854.
- Dutta N., Gupta A., Mazumber D., Banerjee S. Down-regulation of locus-soecific human lymphocyte antigen class I expression in Epstein-Barr virus-associated cancer // Cancer.-2006.-Vol. 106.-P. 1685−1693.
- Eder J.P., Kantoff P.W., Roper K. et al. A phase I trial of a recombinant vaccinia virus expressing prostate-specific antigen in advanced prostate cancer // Clin. Cance Res.2000.-Vol. 6.-P. 1632−1638.
- Egen J.G., Juhns M.S., Allison J.P. CTLA-4: new insights into its biological function and use in tumor immunotherapy//Nat. Immunol.-2002. Vol. 3.-P. 611−618.
- Ehrlich P. Ueber den jetzigen stand der Karzinomforschung // Ned. Tijdschr. Geneeskd. -1909.-Vol. 5.-P. 273−290.
- Espinoza-Delgano I. Cancer vaccines // Oncologist. 2002. — Vol. 7, № 2. — P. 20−33.
- Fong L., Hou Y., Rivas A. et al. Altered peptide ligand vaccination with Flt3 ligand expanded dendritic cells for tumor immunotherapy // Proc. Natl. Acad. Sci. USA.2001.-Vol. 98.-P.8809 8814.
- Garrido F., Ruiz-Cabello F., Cabrera T. et al. Implications for immunosurveillance of altered HLA class I phenotypes in human tumors // Immunol. Today. 1997. — Vol. 18. — P. 89−95.
- GeigerJ.D., Hutchinson R.J., Hohenkirk L.F. et al. Vaccination of pediatric solid tumor patients with tumor lysate pulsed dendritic cells can expand specific T cells and mediate tumor regression // Cancer Res. 2001. — Vol. 61. — P. 8513 8519.
- Glynne Я, Powis S., Beck S. et al. A proteasome related gene between the two abc transporter loci in the calls II region of the human MHC // Nature. 1991. — Vol. 353. -P. 357−360.
- Gulley J., Chen A.P., Dahut W. et al. Phase I study of a vaccine using recombinant vaccinia virus expressing PSA (rV-PSA) in patients with metastatic androgen-independent prostate cancer // Prostate. 2002. — Vol. 53. — P. 109−117.
- Hahne M., Rimoldi D., Schroter M. et al. Melanoma cell expression of Fas (Apo-1/CD95) ligand: implications for tumor immune escape // Science. 1996. — Vol. 274, № 5291.-P. 1363−1366.
- Hanson H.L., Donermeyer D.L., Ikeda H. et al. Eradication of established tumors by CD8+ T cell adoptive immunotherapy // Immunity. 2000. — Vol. 13. — P. 265−277.
- Haywood G.R., McKhann C.F. Antigenic specificities on murine sarcoma cells. Reciprocal relationship between normal transplantation antigens (H-2) and tumor-specific immunogenicity // J. Exp. Med. 1971. — Vol. 133, № 6. — P. 1171−1187.
- Heinzel A.S., Grotzke J.E., Lines R.A. et al. HLA-E-dependent presentation of Mtb-derived antigen to human CD8+ T cells // J. Exp. Med. 2002. — Vol. 196, № 11. — P. 1473−1481.
- Hersey P., Menzies S.W., Halliday G.M. et al. Phase I/II study of treatment with dendritic cell vaccines in patients with disseminated melanoma // Cancer Immunol. Immunother. 2003. — Vol. 53. — P. 125 134.
- Hirano F" Капеко К., Tamura H. et al. Blockade of B7-H1 and Pd-1 by monoclonal antibodies potentiates cancer therapeutic immunity // Cancer Res. 2005. — Vol. 65, № 3.-P. 1089−1096.
- Holtl L" Zelle-Rieser C., Gander H. et al. Immunotherapy of metastatic renal cell carcinoma with tumor lysate pulsed autologous dendritic cells // Clin. Cancer Res. -2002.-Vol. 8.-P. 3369 3376.
- Horig H., Lee D.S., Conkright W. et al. Phase I clinical trial of a recombinant canarypoxvirus (ALVAC) vaccine expressing human carcinoembryonic antigen and the B7.1 co-stimulatory molecule // Cancer Immunol. Immunother. 2000. — Vol. 49. — P. 504 514.
- Humphrey M.B., Lanier L.L., Nakamura M.C. Role of ITAM-containing adapter proteins and their receptors in the immune system and bone // Immunol. Rev. 2005. -Vol. 208. — P. 50−65.
- Iwai Y., Ishida M., Tanaka Y. et al. Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade // Proc. Natl. Acad. Sci. USA. 2002. — Vol. 99. — P. 12 293−12 297.
- Jager E., Gnjatic S" Nagata Y. et al. Induction of primary NY-ESO-1 immunity: CD8+ T lymphocyte and antibody responses in peptide-vaccinated patients with NY-ESO-1+ cancers // Proc. Natl. Acad. Sci. USA. 2000. — Vol. 97. — P. 12 198−12 203.
- Janetzki S., Palla D., Rosenhauer V. et al. Immunization of cancer patients with autologous cancer-derived heat schock protein gp96 preparations: a pilot study // Int. J. Cancer.-2000.-Vol. 88.-P.232 238.
- Juffs Я, Fowler N., Saal R et al. В cell chronic lymphocytic leukaemia cells have reduced capacity to upregulate expression of MHC class I in response to interferon-gamma // Pathology. 2004. — Vol. 36. — P. 69−76.
- Kagari Т., Tanaka D., Doi H" Shimozato T. Essential role of Fey receptors in anti-type II collagen antibody-induced arthritis//J. Immunol. -2003. Vol. 170. — P. 4318−4324.
- Khakoo S.I., Rajalingam R, Shum B.P. et al. Rapid evolution of NK cell receptor systems demonstrated by comparison of chimpanzees and humans // Immunity. 2000. -Vol. 12.-P. 687−698.
- Khakoo S.I., Thio C.L., Martin M.P. et al. HLA and NK cell inhibitory receptor genes in revolving hepatitis С virus infection // Science. -2004. vol. 305. P. 872−874.
- Khleif S.N., Abrams S.I., Hamilton J.M. et al. A phase I vaccine trial with pepetides reflecting ras oncogene mutations of solid tumors // J. Immunother. 1999. — Vol. 22. -P. 155−165.
- Kikuchi-Maki A., Catina T.L., Campbell K.S. Cutting edge: KIR2DL4 transduces signals into human NK cells through association with the Fc receptor gamma protein // J. Immunol. 2005. — Vol. 174. — P. 3859−3863.
- Kikuchi-Maki A., Yusa S., Catina T.L., Campbell K.S. KIR2DL4 is an IL-2 regulated NK cell receptor that exhibits limited expression in humans but trigger strong INF-gamma production // J. Immunol. 2003. — Vol. 171. — P. 3415−3425.
- Klebanoff C.A., Gattinoni L., Torabi-Parizi P. et al Central memory self/tumor-reactive CD8+ T cells confer superior antitumor immunity compared with effector memory T cells // Proc. Natl. Acad. Sci. USA. 2005. — Vol. 102, № 27. — P. 9571−9576.
- Klein G. Tumor antigens // Annu. Rev. Microbiol. 1966. — Vol. 20. — P. 223−252.
- Knapp L.A., Cadavid L.F., Watkins D.I. The MHC locus is the most well conserved of all known primate class I histocompatibility genes // J. Immunol. 1998. — Vol. 160. -P. 189−196.
- Kohler G., Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity // Nature. 1975. — Vol. 256. — P. 495−497.
- Koller В., Geraghty D" Shimizu Y. et al. HLA-E. A novel HLA class I gene expressed in resting T lymphocytes // J. Immunol. 1988. — Vol. 41. — P. 897−904.
- Kryczek I., Zou L" Rodriguez P. et al. B7-H4 expression identifies a novel suppressive macrophage population in human ovarian carcinoma // J. Exp. Med. 2006. — Vol. 203, № 4.-P. 817−820.
- Laemmli U.K. Cleavage of structural proteins during the assembly of the head of bacteriophage T4 // Nature. -1970. Vol. 227. — P. 680−685.
- Lanier L.L. NK cell recognition // Annu. Rev. Immunol. 2005. — Vol. 23. — P. 225−274.
- Lanier L.L., Corliss B.C., Wu J. et al. Immunoreceptor DAP12 bearing a tyrosine-based activation motif is involved in activating NK cells // Nature. 1998. — Vol. 391. — P. 703−707.
- Larin S.S., Georgiev G.P., Kiselev S.L. Gene transfer approaches in cancer immunotherapy // Gene Ther. 2004. — Vol. 1. — P. S18−25.
- Lee N" Goodlett D" IshitaniA. et al. HLA-E surface expression depends on binding of TAP-dependent peptides derived from certain HLA class I signal sequences // J. Immunol. 1988,-Vol. 160.-P. 4951 4960.
- Lee N., Llano M., Carretero M. et al. HLA-E is a major ligand for the natural killer inhibitory receptor CD94/NKG2A // Proc. Natl. Acad. Sci. USA. 1998. — Vol. 95. — P. 5199 5204.
- Lee P., Wang F., KuniyoshiJ. et al. Effects of interleukin-12 on the immune response to a multipeptide vaccine for resected metastatic melanoma // J. Clin. Oncol. 2001. — Vol. 19.-P. 3836−3847.
- Leibson P.J. The regulation of lymphocyte activation by inhibitory receptors // Curr. Opin. Immunol. 2004. — Vol. 16(3). — P. 328−336.
- Leibson P.J. The regulation of lymphocyte activation by inhibitory receptors // Curr. Opin. Immunol.-2004.-Vol. 16.-P. 328 336.
- Lemberg M.K., Bland F.A., Weihofen A. et al. Intramembrane proteolysis of signal peptides: as essential step in the generation of HLA-E epitop // J. Immunol. 2001. -Vol. 167.-P.-6441−6446.
- Maker A. V., Attia P., Rosenberg S.A. Analysis of the cellular mechanism of antitumor responses and autoimmunity in patients treated with CTLA-4 blockade // J. Immunol. -2005. Vol. 175, № 11. — P. 7746−7754.
- Malmberg K, Levitsky V., Norell H. et al. IFN-gamma protects short-term ovarian carcinoma cell lines from CTL lysis via a CD94/NKG2A-dependent mechanism // J. Clin. Invest.-2002.-Vol. 110.-P. 1515−1523.
- Marin R., Ruiz-Cabello F., Pedrinaci S. Analysis of HLA-E expression in human tumors // Immunogenetics. 2003. — Vol. 54, № 11. — P. 767−75.
- Marshall J.L., Hawkins M.J., Tsang K.Y. et al. Phase I study in cancer patients of a replication-defective avipox recombinant vaccine that expresses human carcinoembryonic antigen Hi. Clin. Oncol. -1999. -Vol. 17.-P. 332 337.
- Met 0., Wang M., Pedersen A.E. et al. The effect of a therapeutic dendritic cell-based cancer vaccination depends on the blockage of CTLA-4 signaling // Cancer Let. 2006. -Vol. 231, № 2.-P. 247−256.
- Michaelsson J., Teixeira de Matos C" Achour A. et al. A signal peptide derived from hsp60 binds HLA-E and interferes with CD94/NKG2A recognition // J. Exp. Med. -2002.-Vol. 196, № 11.-P. 1403−1414.
- Miller J.D., Weber D.A., Ibegbu C. et al. Analysis of HLA-E peptide-binding specificity and contract residues in bound peptide required for recognition by CD94/NKG2 // J. Immunol.-2003.-Vol. 171.-P. 1369−1375.
- Mitchell M.S., Кап-Mitchell J., Morrow P.R. et al. Phase I trial of large multivalent immunogen derived from melanoma lysates in patients with disseminated melanoma // Clin. Cancer Res. 2004. — Vol. 10. — P. 76 83.
- Mocellin S., Mandruzzato S., Bronte V., Marincola F.M. Cancer vaccines: pessimism in check//Nat. Med.-2004.-Vol. 10, № 12.-P. 1278−1279.
- Muhlfeld A.S., Segerer S., Hudkins K. et al. Deletion of the Fey receptor lib in thymic stromal lymphopoietin transgenic mice aggravates memranoproliferative glomerulonephritis//Am. J. Pathol.-2003.-Vol. 163.-P. 1127−1136.
- Muta Т., Kurosaki Т., Misolovin Z. et al. A 13 amino-acid motif in the cytoplasmic domain of Fc gamma RIIB modulates B-cell receptor signaling // Nature. 1994. — Vol. 368.-P. 70−73.
- Nemunaitis J., Sterman D" Jablons D. et al. Granulocyte-macrophage colony-stimulating factor gene-modified autologous tumor vaccines in non-small-cell lung cancer // J. Natl. Cancer Inst. 2004. — Vol. 96. — P. 326 331.
- Nestle F.O., Alijaqic S., Gilliet M. et al. Vaccination of melanoma patients with peptide-or tumor lysatepulsed dendritic cells // Nat. Med. 1998. — Vol. 4. — P. 328 332.
- Nishimura H" Nose M., Hiai H. et al. Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM-motif-carrying immunoreceptor // Immunity. 1999. — Vol. 11. — P. 141−151.
- O’Callaghan C. Molecular basis of human natural killer cell recognition of HLA-E (human leukocyte antigen-E) and its relevance to clearance of pathogen-infected and tumour cells // Clin. Sci. 2000. — Vol. 99. — P. 9−17.
- O’Callaghan C.A., Tormo J., Willcox B.E. et al. Structural features impose tight peptide binding specificity in the nonclassical MHC molecule HLA-E // Mol. Cell. 1998. -Vol. l.-P. 531−541.
- Okazaki Т., Iwai Y., Honjo T. New regulatory co-receptors: inducible co-stumulator and PD-1 // Curr. Opin. Immunol. 2002. — Vol 14. — P. 779−782.
- Old L., Boyse E.A. Immunology of experimental tumors // Annu. Rev. Med. 1964. -Vol. 15.-P. 167−186.
- Ortiz-Narvarete V., Seelig A., Gernold M. et al. Subunits of the 20S proteasome (multicatalytic proteinase) encoded by major histocompatibility complex // Nature. -1991.-Vol. 353.-P. 662−762.
- Overwijk W.W., Theoret MR., Finkelstein S.E. et al. Tumor regression and autoimmunity after reversal of a functionally tolerant state of self-reactive CD8+ T cells // J. Exp. Med. 2003. — Vol. 198. — P. 569−580.
- Pace J.L., Russell S.W., R.D. Schreiber et al. Macrophage activation: priming activity from a T-cell hybridoma is attributable to interferon-gamma // Proc. Natl. Acad. Sci. USA. 1983. — Vol. 12. — P. 3782−3786.
- Palmisano G., Contardi E., MorabitoA. et al. HLA-E surface expression is independent of the availability of HLA class I signal sequence-derived peptides in human tumor cell lines // Hum. Immunol. 2005. — Vol. 66. — P. 1−12.
- Peipp M., Valerius T. Bispecific antibodies targeting cancer cells // Biochem. Soc. Trans. 2002. — Vol. 30, № 4. — P. 507−511.
- Pietra G" Romagnani C., Mazzarino P. et al. HLA-E-restricted recognition of cytomegalovirus-derived peptides by human CD8+ cytolytic T lymphocytes // Proc. Natl. Acad. Sci. USA.-2003.-Vol. 100, № 19.-P. 10 896−10 901.
- Plunkett T.A., Miles D.W. New biological therapies for breast cancer // Int. J. Clin. Pract. 2002. — Vol. 56, № 4. — P. 261−266.
- Poszepczynska-Guigne E., Schiavon V., D’Incan M. et al. CD158k/KIR3DL2 is a new phenotypic marker of Sezary cells: relevance for the diagnosis and follow-up of Sezary syndrome // J. Invest. Dermatol. 2004. — Vol. 122, № 3. — P. 820−823.
- Rajagopalan S., Long E.O. A human histocompatibility leukocyte antigen (HLA)-G-specific receptor expressed on all natural killer cells // J. Exp. Med. 1999. — Vol. 189. -P. 1093−1100.
- Ravetch J. V., BollandS. IgG Fc receptors // Annu. Rev. Immunol. 2001. — Vol. 19. — P. 275 290.
- Ravetch J. V., Lanier L.L. Immune inhibitory receptors // Science. 2000. — Vol. 290. -P. 84−89.
- Reits E.A., Benham A.M., Plougastel B. et al. Dynamics of proteasome distribution in living cells // EMBO J. 1997. — Vol. 16. — P. 6087−6094.
- Restifo N.P., Esquivel F., Asher A.L. etal. Defective presentation of endogenous antigens by a murine sarcoma. Implications for the failure of an anti-tumor immune response//J. Immunol.-1991.-Vol. 147, № 4.-P. 1453−1459.
- Robbie-Ryan M., Tanzola M.B., Secor V.H., Brown M.A. Cutting Edge: Both activating and inhibitory Fc receptors expressed on mast cells regulate experimental allergic encephalomyelitis disease severity//J. Immunol.-2003.-Vol. 170.-P. 1630−1634.
- Robinson J., Waller M, Par ham P. et al. IMGT/HLA and IMGT/MHC: sequence databases for the study of the major histocompatibility complex // Nucleic Acids Res.2003.-Vol.31.-P. 311−314.
- Rosenberg S.A., Dudley M.E. Cancer regression in patients with metastatic melanoma after the transfer of autologous antitumor lymphocytes // Proc. Natl. Acad. Sci. U S A.2004.-Vol. 101.-P. 14 639−14 645.
- Rosenberg S.A., YangJ.C., Restifo N.P. Cancer immunotherapy: moving beyond current vaccines // Nat. Med. 2004. — Vol. 9. — P. 909−915.
- SambrookJ., Fritsch E" Maniatis T. Molecular Cloning: A Laboratory Manual (2nd edn) // Cold Spring Harbor Laboratory Press: Cold Spring Harbor. 1989. — P. 1847 1875.
- Sato Y. et al. A phase I trial of cytotoxic T-lymphocyte precursor-oriented peptide vaccines for colorectal carcinoma patients // Br. J. Cancer. 2004. — Vol. 90. — P. 13 341 342.
- Scheibenbogen C., Schmittel A., Keilholz U. et al. Phase 2 trial of vaccination with tyrosinase peptides and granulocyte-macrophage colony-stimulating factor in patients with metastatic melanoma//J. Immunother. -2000. Vol. 23. — P. 275−281.
- Seliger В., Ritz U" Ferrone S. Molecular mechanisms of HLA class I antigen abnormalities following viral infection and transformation // Int. J. Cancer. 2006. -Vol. 118.-P. 129−138.
- Sica G.L., Choi I.-H., Zhu G. et al. B7-H4, a molecule of the B7 family, negatively regulates T cell immunity // Immunity. 2003. — Vol. 18. — P. 849−861.
- Sijts A., Ruppert Т., Rehermann B. et al. Efficient generation of a Hepatitis В virus cytotoxic T lympjocyte epitote requires the structural features of immunoproteasomes // J. Exp. Med. -2000, — Vol. 191. P. 503−513.
- Silverstein A.M. History of Immunology // Academic, San Diego, CA. 1989.
- Srivastava P.K., Udono H. Heat-shock protein-peptide complexs in cancer immunotherapy // Curr. Opin. Immunol. 1994. — Vol. 6. — P. 728−732.
- Stift A., Friedl J., Dubsky P. et al. Dendric cell-based vaccination in solid tumor // J. Clin. Oncol. 2003. — Vol. 21. — P. 135−142.
- Strehl В., Seifert U., Kriiger E. et al. Interferon-y, the functional plasticity of the ubiquitin-proteasome system, and MHC class I antigen processing // Immunol. Rev. -2005.-Vol. 207.-P. 19−30.
- Su Z, Dannull J., Heiser A. et al. Immunological and clinical responses in metastatic renal cancer patients vaccinated with tumor RNA-transfected dendritic cells // Cancer Res.-2003.-Vol. 63.-P.2128 2133.
- Suto Y., Maenaka K., Yabe T. et al. Chromosomal localization of the human natural killer cell class I receptor family genes to 19ql3.4 by fluorescence in situ hybridization // Genomics. 1996. — Vol. 35. — P. 270−272.
- Tanaka S., Harada M., Mine T. et al. Peptides vaccination for patients with melanoma and other types of cancer based on pre-existing peptide-specific cytotoxic T-lymphocyte precursors in the periphery // J. Immunother. 2003. — Vol. 26. — P. 357−366.
- Taylor P.A., Lees C.J., Fournier S. et al. B7 expression on T cells down-regulates immune responses through CTLA-4 ligation via T-T interactions // J. Immunol. 2004. -Vol. 172.-P. 34−39.
- Tivol E.A., Bordello F., Schweitzer A.N. et al. Loss of CTLA-4 leads to massive lymphoproliferation and fatal multi-organ tissue destruction, revealing a critical negative regulatory role of CTLA-4 // Immunity. 1995. — Vol. 3. — P. 541−547.
- Tomasec P., Braud V., Rickards C. et al. Surface expression of HLA-E, an inhibitor of natural killer cells, enhances by human cytomegalovirus gpUL40 // Science. 2000. -Vol. 287.-P. 1031−1033.
- Torre-Amione G., Beauchamp R.D., Koeppen #., BHPark et al. A highly immunogenic tumor transfected with a murine transforming growth factor type B1 cDNA escapes immune surveillance // Proc. Natl. Acad. Sci. USA. 1990. — Vol. 87. — P. 1486−1490.
- Trauth B.C., Klas C., Peters A.M. et al. Monoclonal antibody-mediated tumour regression by induction of apoptosis // Science. 1989. — Vol. 245. — P. 301−305.
- Veda H., Howson J.M.M., Esposito L. et al. Association of the T-cell regulatory gene CTLA-4 with susceptibility to autoimmune disease // Nature. 2003. — Vol. 423. — P. 506−511.
- Ulbrecht M" Martinozzi S., Grzeschik M. et al. Cutting edge: the human cytomegalovirus UL40 gene product contains a ligand for HLA-E and prevents NK cell-mediated lysis // J. Immunol. 2000. — Vol. 164. — P. 5019−5022.
- Urban J.L., Burton R.C., Holland J.M. et al. Mechanisms of syngeneic tumor rejection. Susceptibility of host-selected progressor variants to various immunological effector cells // J. Exp. Med. 1982. — Vol. 155, № 2. — P.557−573.
- Van Driel W.J., Ressing M.E., Kenter G.G. et al. Vaccination with HPV16 peptides of patients with advanced cervical carcinoma // Eur. J. Cancer. 1999. — Vol. 22. — P. 155 156.
- Vance R.E., Kraft J. R, Altman J.D. et al. Mouse CD94/NKG2A is a natural killer cell receptor for the nonclassical major histocompatibility complex (MHC) class I molecule Qa-l (b)//J. Exp. Med.-1998.-Vol. 188.-P. 1841−1848.
- Verheyden S" Bernier M., Demanet C. Identification of natural killer cell receptor phenotypes associated with leukemia // Leukemia. 2004. — Vol. 12. — P. — 2002−2007.
- Vivier E., Anfossi N. Inhibitory NK-cell receptors on T-cells: witness of the past. Actors ofthe future//Nat. Reviews. Immunology. -2004. -Vol. 4. P. 190−198.
- Vonderheide R.H., Domchek S.M., Schultze J.L. et al. Vaccination of cancer patients telomerase induces functional antitumor CD8+ T lymphocytes // Clin. Cancer Res. -2004.-Vol. 10.-P. 828−839.
- Wagtmann N., Rajagopalan S., Winter C.C. et al. Killer cell inhibitory receptors specific for HLA-C and HLA-B identified by direct binding and by functional transfer // Immunity. 1995. — Vol. 3. — P. 801−809.
- Watanabe N., Gavrieli M., Sedy J. R et al. BTLA is a lymphocyte inhibitory receptor with similarities to CTLA-4 and PD-1 // Nat. Immunol. 2003. — Vol. 7. — P. 670−679.
- Watanabe Т., Okano M., Hattori H. et al. Roles of FcyRIIb in nasal eosinophilia and IgE production in murine allergic rhinitis // Am. J. Respir. Crit. Care Med. 2004. -Vol. 169.-P. 105−112.
- Williams A.P., Bateman A.R., Khakoo S.I. KIR and their role in disease // Nature Immun. -2005.-Vol. 5(4).-P. 226−240.
- Yajima K., Nakamura A., Sugahara A., Takai T. FcyRIIB deficiency with Fas mutation is sufficient for the development of systemic autoimmune disease // Eur. J. Immunol. -2003.-Vol. 33.-P. 1020−1029.
- Yusa S.-I., Campbell K.S. Src homology region 2-containing protein tyrosine phosphatase-2 (SHP-2) can play s direct role in the inhibitory function of killer cell Ig-Like receptors in human NK cells // J. Immunol. 2003. — Vol. 170. — P. 4539−4547.
- Zinzani P.L., Lauria F" Salvucci M. et al. Hairy-cell leukemia and alfa-interferon treatment: long-term responders // Haematologica. 1997. — Vol. 82. — P. 152−155.1. Благодарности
- Я выражаю искреннюю благодарность своему научному руководителю Сергею Сергеевичу Ларину за предоставление возможности выполнения работы, за терпение и чуткое руководство, а также критическое чтение диссертации.
- Спасибо всем сотрудникам различных подразделений ИБГ РАН, которые помогали решать технические вопросы обеспечения и проведения работ.